lymphoid cells

[Molecular Partners AG] Molecular Partners AG announced a research collaboration with University of Bern, to advance the development of the company’s wholly owned acute myeloid leukemia candidate, MP0533, into the clinic.

[Vincerx Pharma, Inc.] Vincerx Pharma, Inc. announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company’s PTEFb/CDK9 inhibitor, for the treatment of diffuse large B cell lymphoma.

[Nature Cell Biology] The authors findings implicated retrotransposable element silencing in hematopoiesis and suggested a cross-talk between the H3.3 loading machinery and the pioneer transcription factor Pu.1.

[Leukemia] By using TL1, a human T-LGL cell line, the authors could show that miR-181a was an actor in T-LGL leukemia, driving STAT3 activation by SOCS3 inhibition and ERK1/2 phosphorylation by DUSP6 inhibition and verified this mechanism in an independent cell line.

[Cell] Researchers identified a gene signature defining CAR and TCR dysregulation and transcription factors, including SOX4 and ID3 as key regulators of CAR T cell exhaustion.

[Blood] Scientists identified PR domain zinc finger protein 1 (PRDM1) i.e., Blimp-1, as a key epigenetic gene associated with terminal T cell differentiation.